BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotech company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, published its full-year financial results for the year ended December 31, 2022; the report also included key business updates. Highlights of the report include the signing of definitive agreements with the Max Planck Society (“MPG”) and the University Medical Center Göttingen, Germany (“UMG”) designed to enable BiondVax to build a pipeline of “bio-better” nanosized VHH antibodies (NanoAbs); notice that the unique physicochemical characteristics of NanoAbs being generated by BiondVax’s scientific partners show several competitive attributes, including greater binding affinity, neutralization at lower drug concentrations, stability at high temperatures, and convenient routes of administration and formulation advantages; and an option for an exclusive worldwide license agreement at pre-agreed financial terms for additional NanoAbs discovered and characterized under the BiondVax-MPG-UMG agreement.
In addition, the company is looking at starting a phase 1/2a clinical trial while continuing to monitor the ongoing evolution of the COVID-19 virus and variants of concern (“VoCs”). “BiondVax’s recent achievements leave me very optimistic about BiondVax’s growth potential and ability to deliver value to our stakeholders,” said BiondVax CEO Amir Reichman in the press release. “This past winter we published exciting data from the proof-of-concept in vivo trial of an inhaled NanoAb therapy. Looking forward, I’m excited to exercise our option to obtain an exclusive license at pre-agreed financial terms to anti-IL-17 NanoAbs targeting safe, effective and convenient treatment of psoriatic lesions; scale up in-house NanoAb manufacturing; and conduct an in vitro proof-of-concept study and potentially also a preclinical trial of the IL-17 NanoAb as a therapy for psoriasis. The BiondVax team, in collaboration with our scientific partners from MPI-NAT and UMG, has worked exceedingly hard to develop best in class capabilities in NanoAb technology-based drug development.”
To view the full press release, visit https://ibn.fm/bz12g
About BiondVax Pharmaceuticals Ltd.
BiondVax Pharmaceuticals is a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases. Since its inception, the company has executed eight clinical trials including a seven-country, 12,400-participant, phase 3 trial of its prior vaccine candidate; the company has also built a state-of-the-art manufacturing facility for biopharmaceutical products. With highly experienced pharmaceutical industry leadership, BiondVax is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with an innovative nanosized antibody (“NanoAb”) pipeline. For more information about the company, please visit www.BiondVax.com
NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://ibn.fm/BVXV
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]
InvestorWire is part of the InvestorBrandNetwork